SCHEMBL1260179

SCHEMBL1260179

C=CCn1c(O[C@H]2CN[C@H](C(=O)OC)C2)nc2ccccc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
CHEK2 O96017 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 7/20 0.41
HPGD P15428 1/20 0.41
P2RX3 P56373 1/20 0.41
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PIM1 P11309 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GRK6 P43250 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1073524 0.91 RXFP1 (0.44) MEN1KMT2ARXFP1TDP1ALDH1A1
SCHEMBL881965 0.89 P2RX3 (0.39) CHEK2RXFP1ALDH1A1HPGDP2RX3
SCHEMBL15096207 0.88 P2RX3 (0.45) MEN1KMT2ARXFP1ALDH1A1P2RX3
SCHEMBL15093669 0.81 ALDH1A1 (0.38) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL15093479 0.79 SMN1; SMN2 (0.40) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL8012771 0.77 P2RX3 (0.45) MEN1KMT2ARXFP1TDP1ALDH1A1
SCHEMBL1260182 0.77 TDP1 (0.44) MEN1KMT2ARXFP1TDP1ALDH1A1
SCHEMBL12934515 0.76 CHEK2 (0.42) MEN1KMT2ACHEK2ALDH1A1HPGD
SCHEMBL1072609 0.76 CHEK2 (0.42) MEN1KMT2ACHEK2ALDH1A1HPGD
SCHEMBL12892991 0.76 PIM1 (0.39) ALDH1A1P2RX3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461107-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-06-11 US disclosed
US-8461107-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2013-06-11 US disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046161-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC MEN1 4761/4885KMT2A 3629/4885CHEK2 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.